Unlock instant, AI-driven research and patent intelligence for your innovation.

A type III procollagen N-terminal peptide nanobody, its coding sequence and its use

A nanobody and sequence technology, applied in the field of biomedicine or biopharmaceuticals, can solve the problems of high cost, low specificity and robustness of detection methods, and high minimum detection limit.

Active Publication Date: 2021-07-06
安徽合创健康生物技术有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because the above technical methods require radioactive labeling or preparation of monoclonal antibodies, the cost is relatively high, and the specificity and robustness of the detection method are not strong, and the minimum detection limit is still high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A type III procollagen N-terminal peptide nanobody, its coding sequence and its use
  • A type III procollagen N-terminal peptide nanobody, its coding sequence and its use
  • A type III procollagen N-terminal peptide nanobody, its coding sequence and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Preparation of Nanobody Phage Display Library

[0028] Collect peripheral blood from dromedary camels, centrifuge at 2000rp for 5min, collect peripheral blood cells (PMBC), add Trizol to extract total RNA, use total RNA as template, oligo(dT)20 and random primer (N9) as primers, prepare cDNA by RT-PCR One strand, use the first strand of cDNA as a template, and perform two rounds of PCR amplification with the following primers;

[0029] Primers for the first round of PCR amplification:

[0030] Upstream primer: 5'-GTCCTGGCTGCTCTTCTACAAGG-3'

[0031] Downstream primer: 5'-GGTACGTGCTGTTGAACTGTTCC-3'

[0032] Primers for the second round of PCR amplification:

[0033] VHHFR1: 5'-ACTGGCCCAGGCGGCCGATGTGCAGCTGCAGGAGTCTGGAGGAGG-3'

[0034] VHHFR4: 5'-ACTGGCCGGCCTGGCCTGAGGAGACGGTGACCAGGGTC-3'

[0035]Camel VHH fragments of 400-500bp were amplified by two rounds of PCR, and the amplified VHH fragments were connected to the pComb3X phage display vector, and E.coliX...

Embodiment 2

[0036] Example 2: Screening and prokaryotic expression of PIIINP nanobody

[0037] 100 μg / mL PIIINP was coated on a 96-well plate, washed with PBS, added to the nanobody phage display library (1011 phage particles), and the enrichment index was monitored by phage ELISA analysis. After three rounds of panning, the collected phage particles were infected with E.coli XL-2 Blue, IPTG-induced expression, the fermentation supernatant was taken, analyzed by HRP-coupled anti-HA-monoclonal antibody ELISA, and a high-affinity nanobody strain was obtained; the plasmid was further transformed into E.coli TOP10', IPTG-induced prokaryotic expression, after Strep tag II-mediated Streptactin Beads 4FF affinity chromatography, a highly expressed PIIINP nanobody was obtained as figure 2 shown.

Embodiment 3

[0038] Example 3: Expression and specificity identification of nanobodies

[0039] 1. Extract the plasmid pComb3X-PIIINP-Nb of the Nanobody gene from Escherichia coli respectively, and sequence the above plasmid using primer TTTACACTTTATGCTTCCGGCT, and obtain a Nanobody amino acid residue sequence (SEQID 8) and its corresponding encoding Nanobody DNA sequence (SEQ ID 9);

[0040] 2. Using the plasmid pComb3X-PIIINP-Nb as a template, the DNA sequence (SEQ ID 9) of the PIIINP nanobody (SEQ ID 8) was subcloned into pET22b, and E.coli BL21 (DE3) was used as the expression host to express recombinantly containing HA-tagged nanobody; after IPTG-induced prokaryotic expression, a highly expressed HA-tagged PIIINP nanobody was obtained by Streptag II-mediated Streptactin Beads 4FF affinity chromatography;

[0041] 3. Using bovine serum albumin BSA as a control, evaluate the specificity of the PIIINP nanobody, use HRP-coupled anti-HA monoclonal antibody as the detection antibody, detec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a VHH chain of a human type III procollagen N-terminal peptide (PIIINP) nanobody, comprising a framework region FR and a complementarity determining region CDR, and discloses the amino acid sequence of the framework region FR1‑4 and the complementarity determining region CDR1‑3 amino acid sequence; the present invention discloses a PIIINP nanobody, and also discloses a DNA molecule, which encodes the VHH chain of the PIIINP nanobody of the present invention or the PIIINP nanobody of the present invention; the present invention also discloses A host cell that can express a nanobody against PIIINP and has a very high affinity; also discloses the use of the nanobody to detect PIIINP, which can be applied to the clinical detection of PIIINP in serum.

Description

technical field [0001] The invention relates to a type III procollagen N-terminal peptide (PIIINP) nanobody, its coding sequence and its use, and belongs to the technical field of biomedicine or biopharmaceuticals. Background technique [0002] Liver fibrosis is one of the main causes of high morbidity and mortality worldwide. Activation and abnormal proliferation of hepatic stellate cells lead to massive secretion and accumulation of extracellular matrix components, such as type III procollagen N-terminal peptide (PIIINP), hyaluronic acid (HA), type IV collagen (CIV), type VI collagen ( CVI), fibromodulin (CXIV, Undulin), laminin (LN), cytohesin C (Tenascin), etc., are one of the main causes of progressive liver fibrosis. Almost all liver diseases, especially common high-incidence liver diseases such as hepatitis B, hepatitis C, alcoholic liver disease, autoimmune or hereditary liver disease, will gradually develop into progressive liver fibrosis and eventually cirrhosis. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/18C12N15/13G01N33/68
CPCC07K16/18C07K2317/565C07K2317/567C07K2317/569C07K2317/92G01N33/6893G01N2333/78G01N2800/085
Inventor 王永中
Owner 安徽合创健康生物技术有限公司